


CLINICAL PATHWAY: Perinatal HIV Exposure Management (for Breastfeeding and Non-Breastfeeding Newborns)

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



CONTACTS: ASHLEY HOWARD, DO | IAN MICHELOW, MD | ALAINA PYLE, MD | NANNETTE KYER, BSN, RN, IBCLC

LAST UPDATED: 08.25.25

©2019 Connecticut Children's Medical Center. All rights reserved.



CLINICAL PATHWAY:**Perinatal HIV Exposure Management (for Breastfeeding and Non-Breastfeeding Newborns)
Appendix A: Antiretroviral Therapy Dosing**THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Antiretroviral Therapy Dosing

*Dosing for treatment based on infant gestational age at birth and post-natal age
For dosing below the recommended ages below, please consult ID*

Infant AVR Dosing

Drug Name	Gestational Age, Current Age	Dose
AZT	≥35 weeks, birth to 6 weeks	4 mg/kg/dose PO BID
NVP	≥37 weeks, birth to 6 weeks	6 mg/kg/dose PO BID
3TC	≥32 weeks, birth to < 4 weeks	2 mg/kg/dose PO BID
3TC	≥ 32 weeks, ≥ 4 weeks to ≤ 6 weeks	4 mg/kg/dose PO BID
RAL	≥37 weeks, birth to 1 week AND weighing at least 2 kg	1.5 mg/kg PO once daily
RAL	≥37 weeks, 1 week AND weighing at least 2 kg	1.5 mg/kg PO BID

3 drug presumptive therapy: AZT, 3TC, and NVP or RAL

NVP Prophylaxis While Receiving Breastmilk

NVP administered starting at birth or after completion of initial prophylaxis ZDV, through 6 weeks after cessation of breastfeeding

Drug Name	Gestational Age, Current Age	Dose
NVP	≥32 weeks gestation, birth to 6 weeks AND weight 2 to <3 kg	10 mg (1 mL) PO once daily
NVP	≥32 weeks, 6 weeks to 6 months	20 mg (2 mL) PO once daily
NVP	≥32 weeks, 6 months to 9 months	30 mg (3 mL) PO once daily
NVP	≥ 32 weeks, 9 months to 18 months	40 mg (4 mL) PO once daily

(10 mg/mL oral syrup)

3TC Prophylaxis While Receiving Breastmilk

3TC administered starting after completion of initial prophylaxis ZDV, through 6 weeks after cessation of breastfeeding

Drug Name	Gestational Age, Current Age, Weight	Dose
3TC	≥32 weeks gestation, from 2 weeks to < 4 weeks	2 mg/kg/dose PO BID
3TC	≥32 weeks, ≥ 4 weeks to 12 months AND 2 to <3 kg	10 mg (1 mL) PO BID
3TC	≥32 weeks, ≥ 4 weeks to 12 months AND 3 to <4 kg	15 mg (1.5 mL) PO BID
3TC	≥32 weeks, ≥ 4 weeks to 12 months AND 4 to <8 kg	25 mg (2.5 mL) PO BID
3TC	≥32 weeks, ≥ 4 weeks to 12 months AND to ≥8 kg	50 mg (5 mL) PO BID

(10 mg/mL oral syrup)

For further dosing information including preterm infants and mothers while breastmilk feeding:

<https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/management-infants-utero-intrapartum-breastfeeding-hiv-exposure?view=full>

CONTACTS: ASHLEY HOWARD, DO | IAN MICHELOW, MD | ALAINA PYLE, MD | NANNETTE KYER, BSN, RN, IBCLC

LAST UPDATED: 08.25.25



CLINICAL PATHWAY:

Perinatal HIV Exposure Management (for Breastfeeding and Non-Breastfeeding Newborns) Appendix B: Informed Discussion for Caregivers Living with HIV and Breastmilk Feeding

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

There are multiple infant feeding options for those who are born to mother's living with HIV. These include formula feeding, banked donor human milk, and breast "chest" feeding.

Based on worldwide data and endorsed by the NIH, the known risk of breastmilk feeding with HIV is not zero but estimated to be < 1%. This risk increases if maternal viral load is not suppressed.

Why parents should consider Breastmilk feeding:

Infant Benefits:

Children who are breastfed experience improved dental health and neurodevelopmental outcomes.

They also have decreased risk of:

- Otitis media
- Diarrhea
- Respiratory Tract infection
- Necrotizing enterocolitis
- SIDS
- Atopic dermatitis
- Asthma
- Celiac Disease
- Crohn's Disease and ulcerative colitis
- Late-onset sepsis in preterm infants
- Type 1 and type 2 diabetes
- Leukemia
- Childhood overweight and obesity

Maternal Benefits:

- Decreased risk of breast, ovarian, endometrial, and thyroid cancers
- Decreased risk of hypertension
- Decreased risk of type 2 diabetes
- Decreased risk of rheumatoid arthritis

Maternal ART compliance is important in breastmilk feeding to help keep baby safe. The infant can be infected through breastmilk feeding because the HIV virus can be in the breastmilk if someone does not take their HIV medication. The baby can receive medication up to 4-6 weeks or longer to help keep this from happening. Maternal viral load testing every 1-2 months is important. If there is detectable maternal virus, then the mother needs to stop breastfeeding and call for further instructions. Infants will also continue to be tested according to a set schedule during this time as well, but at least every 3 months.

When someone is breastmilk feeding it is recommended mix feed with formula as little as possible, as older studies showed a higher rate of infant HIV infection with "mixed" feeding.

When should formula be considered?

- The infant is losing weight
- The breastmilk supply is not yet established
- There is not enough stored breast milk

When should solid foods be introduced? Solid foods should be introduced at 6 months of age when breastmilk feeding with HIV.

It is important to stop breastfeeding if: A mother has mastitis (swollen, red, and tender breasts) or open sores/bleeding from the breast. It is important to pump during this time and discard the breastmilk. Stored frozen breastmilk can be safely given at this time.

References can be accessed at:

www.aap.org/en/patient-care/breastfeeding/breastfeeding-overview/

<https://clinicalinfo.hiv.gov/en/guidelines/perinatal/infant-feeding-individuals-hiv-united-states>

CONTACTS: ASHLEY HOWARD, DO | IAN MICHELOW, MD | ALAINA PYLE, MD | NANNETTE KYER, BSN, RN, IBCLC

LAST UPDATED: 08.25.25

